Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.34 |
| ▸ | DRD3 | P35462 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7163205 | 0.85 | CYP1A2 (0.38) | MEN1KMT2ACYP3A4PTGS1DRD3 | |
| SCHEMBL12168630 | 0.79 | — | — | |
| SCHEMBL17031888 | 0.77 | CYP1A2 (0.34) | MEN1KMT2ACYP3A4PTGS1DRD3 | |
| SCHEMBL25766108 | 0.76 | MAPT (0.33) | CYP1A2GAA | |
| SCHEMBL2620018 | 0.74 | MAPT (0.50) | MEN1KMT2AGAALMNAPOLB | |
| SCHEMBL13237230 | 0.73 | — | — | |
| SCHEMBL14889348 | 0.73 | CYP1A2 (0.34) | MEN1KMT2ACYP3A4PTGS1DRD3 | |
| SCHEMBL10363649 | 0.70 | — | — | |
| SCHEMBL29868840 | 0.70 | SLC6A3 (0.49) | — | |
| SCHEMBL31022902 | 0.70 | CHRNB2 (0.46) | MEN1KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8558011-B2 | Cold menthol receptor-1 antagonists | JANSSEN PHARMACEUTICA, NV (BE) | 2013-10-15 | — | — | US | disclosed |
| US-20120053347-A1 | COLD MENTHOL RECEPTOR-1 ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053347-A1 | COLD MENTHOL RECEPTOR-1 ANTAGONISTS | TRPM8, TRPM5, TRPM7 | MEN1 652/4885KMT2A 1432/4885CYP3A4 1655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.